Acute 40% (PCDH19, GABRG2, anti-NMDAR encephalitis, mycoplasma post-infectious encephalitis), progressive 10% (RE), SE in defined electroclinical syndrome 30% (LGS, DR GE, non-ketotic hyperglycinemia), unknown 20% (NORSE/FIRES). This evidence concerns the gene GABRG2 and encephalitis.